Analysis of the Twist Bioscience Stock:
Robert W Baird maintains the Outperform rating on Twist Bioscience stock. He cuts the price target to $33 from $56 per share.
Barclays lowers the price target to $43 from $45. They maintain the Outperform rating on Twist Bioscience stock.
SVB Leerink maintains the Market Perform rating and lowers the price target to $30 from $45.
Twist Bioscience Stock Statistics:
The average analyst target price for Twist Bioscience stock over the next 12 months is USD 39.83. Based on 4 analysts’ findings.
The average analyst recommendation for Twist Bioscience stock is Buy. Twist Bioscience stock analysis by Stock Target Advisor is Slightly Bearish. Based on 3 positive and 5 negative indications.
The stock price of Twist Bioscience was USD 24.81 at the most recent closure. The share price of Twist Bioscience Corp. changed by -36.98% over the previous week, -14.03% over the previous month, and -77.57% over the previous year.
About Twist Bioscience Corp. (TWST:NSD)
The synthetic biology business Twist Bioscience Corporation creates and markets synthetic DNA-based goods. The company’s DNA synthesis platform might produce synthetic DNA. This might get done by writing DNA onto silicon chips.
It offers artificial DNA-based goods such as:
antibody libraries for drug discovery, and
DNA as a medium for digital data storage.
To create cutting-edge sequencing technologies, the business has relationships with:
Victorian Clinical Genetic Services,
Kyowa Kirin Pharmaceutical Research, Inc.,
deepCDR Biologics AG,
Additionally, it collaborates on research with Boehringer Ingelheim International GmbH. They find therapeutic antibodies against various targets using proprietary antibody libraries. California’s South San Francisco serves as the corporate headquarters for Twist Bioscience. The company got founded in 2013.
Twist Bioscience had a scathing report issued by a short seller. Scorpion Capital sank the stock by over 20 percent. Bioscience reacted by labelling the document “highly misleading”. They accused it of containing “many distortions and inaccuracies”.
Rates for DNA products that get used are set below the whole cost of manufacturing. These get used in biomedical research and diagnostic development. Scorpion referred to Twist’s finances as “a ticking time bomb.”
Twist technology gets based on “a proprietary semiconductor-based synthetic DNA manufacturing process. It features a high-throughput silicon platform. This enables the business to produce genes more cheaply. It also helps in producing greater quantities than with earlier methods. All the while occupying the same amount of physical space.
Scorpion contrasted this assertion with the tale of Theranos. Arguing that Twist continues to use conventional techniques to piece genes together. The famed blood testing business used rivals’ tools to fabricate lab findings. Especially after its own apparatus broke down.
Scorpion Previous Targets
Scorpion has targeted several synthetic biology companies before, including Twist. In October 2021, a month after Ginkgo Bioworks went public in a $1.6 billion SPAC sale. It got targeted by Scorpion and got their work called a “hoax for the ages.” After that, Ginkgo increased its pledges to buy DNA synthesis equipment from Twist. It prepares to expand its cell programming initiatives. They are relying on the weaving industry to do so.
Scorpions Take on The “Factory of the Future”
Another section of the paper focused on Twist’s planned “Factory of the Future,”. A 110,000-square-foot building south of Portland, Oregon. Which will dramatically increase the company’s capacity for DNA manufacture. When the $100 million hub launches at the beginning of next year.
Scorpion deemed it improbable and cited interior images of the facility. Twist released these on its Facebook page in July and August. Those pictures revealed a lack of scientific equipment. The company also sent a private investigator to the place. Scorpion stated that the images it used to support its claims depicted:
- A deserted parking lot,
- A calm loading dock/construction area,
- Roughly a dozen office workers seated in an open and largely vacant floorplan.
Twist responded by stating that it:
Remains focused on its objective to promote health and sustainability. By manufacturing DNA at scale and on building its business. Including shipping product from the Factory of the Future in January 2023.”
Fundamental Analysis for Twist Bioscience Stock:
Positive Fundamentals of Twist Bioscience Stock:
High market capitalization. This organization is among the top quartile and is one of the biggest in its industry. These businesses are more reliable.
Superior returns on risk. In the top quartile, Twist Bioscience stock has outperformed its sector rivals. On a risk-adjusted basis over the course of at least a 12-month holding period.
Superior growth in revenue. Compared to its industry, Twist Bioscience stock has been in the top quartile. Analysis over the previous five years has been in the top quartile.
Negative Fundamentals of Twist Bioscience Stock:
Excessive volatility. Over the past five years, this company’s total returns have been erratic. They have been higher than the industry average. If you plan to invest in Twist Bioscience stock, be sure your risk tolerance is adequate.
Compared to book value, it’s overpriced. On a price-to-book value basis, the stock is selling at a premium to the median of its peer group.
Poor cash flow. The last four quarters saw a negative total cash flow for the organization.
Free cash flow that is negative. In the last four quarters, the company’s overall free cash flow was negative.
Low growth in earnings. Compared to its sector, Twist Bioscience stock earnings growth was lower than average. This is a 5-year average median earning growth statistic.
Conclusion of Analysis
The fundamental analysis for Twist Bioscience stock is Slightly Bearish with a score of 3.7 out of 10.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.